Overview
On October 31, the 2026 Full-Lifecycle Health Innovation Forum was held in Nansha, Guangzhou, with about 200 participants discussing medical-insurance synergy and full-process health management. Former CBIRC vice-chair Huang Hong argued commercial health insurance should stop competing with basic medical insurance for existing stock and instead fill gaps and raise quality. Fosun’s co-CEO said commercial insurance is about 10% of the payment structure and should rise to 20%–30%.
Background & Interpretation
1. Regulatory & Industry Context
Aging is reshaping health-security logic: China has 325 million people over 60, with about 50 million disabled or semi-disabled. The 15th Five-Year Plan for National Health (July 2026) explicitly promotes deeper integration of commercial health insurance with health management. Regulators have called for a prevention–management–protection service system, moving the industry from selling policies to managing health.
2. Core Drivers & Underlying Mechanisms
Three forces drive the shift: technology (genomics and targeted therapy turn once-random risks into manageable ones, weakening static actuarial models), demographics (growing elderly and chronic-disease groups with layered needs), and medical insurance (basic coverage’s expansion squeezes homogeneous products). Commercial health insurance’s core turf shifts to innovative drugs, high-end care, long-term nursing and rare diseases—exactly where basic insurance cannot reach.
3. Market Structure & Industry Chain Impact
Insurers are acting: PICC’s health-management unit launched; Ping An Health extended intervention from hospital to home; Fosun United Health embedded full-lifecycle management into policy clauses, linking wearables and tertiary hospitals—one product exceeded RMB 100m in a year with 98% service usage. But health management long suffers low usage and no one pays; payment innovation like base fee plus risk-adjusted quality bonus is needed.
Implications & Outlook
Near term, medical-insurance synergy should move from concept to scaled products and data loops. Watch: credible evaluation of health-management outcomes, the payment boundary between medical and commercial insurance, and the commercial-nurture-then-medical-inclusion pathway for innovative drugs.
Takeaways for Industry Participants
Insurers should embed health management into policy clauses with payment loops; medical institutions can supply professional risk-reduction resources; tech firms can provide wearable and data platforms; investors can target the insurance + health management + innovative drugs ecosystem.
This column compiles industry information and shares technical perspectives; it does not constitute investment advice.